By Fineline Cube 
Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced a non-exclusive license agreement with BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235). This agreement grants BeOne access to Neowise’s antigen-specific TCR molecule, which is expected to facilitate the development of next-generation universal cell therapies based on BeOne’s iPSC platform.
Financial Terms and Collaboration Benefits
Under the terms of the agreement, Neowise will receive an undisclosed upfront payment and is eligible for development, regulatory, and commercial milestone payments, as well as sales commission. This partnership highlights the potential of Neowise’s TCR molecule to enhance BeOne’s cell therapy pipeline and drive innovation in the treatment of solid tumors.-Fineline Info & Tech